Home Healthcare Biotechnology Infectious Disease Diagnostics Market

Infectious Disease Diagnostics Market Size, Share & Trends Analysis Report By Application (Hepatitis, Human Immunodeficiency Virus, Chlamydia Trachomatis Genital Infection, Gonorrhea, Hospital-Acquired Infections, Human Papillomavirus, Tuberculosis, Influenza), By Product (Assays, Kits & Reagents, Instruments, Services & Software), By Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics, DNA Microarray, Clinical Microbiology, DNA Sequencing & Next-Generation Sequencing), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Last Updated: August 18, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Infectious Disease Diagnostics Market, By Applications 2022-2034 (USD MILLION/ Units)
    1. Hepatitis
    2. Human Immunodeficiency Virus (HIV)
    3. Chlamydia Trachomatis Genital Infection
    4. Gonorrhea (CT/NG)
    5. Hospital-Acquired Infections
    6. Human Papillomavirus (HPV)
    7. Tuberculosis (TB)
    8. Influenza
  2. Infectious Disease Diagnostics Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Assays, Kits, and Reagents
    2. Instruments
    3. Services and Software
  3. Infectious Disease Diagnostics Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Polymerase Chain Reaction (PCR)
    2. Isothermal Nucleic Acid Amplification Technology (INAAT)
    3. Immunodiagnostics
    4. DNA Microarray
    5. Clinical Microbiology
    6. DNA Sequencing and Next-Generation Sequencing (NGS)
  4. Regional Infectious Disease Diagnostics Market
    1. North America
      1. North America Infectious Disease Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
      2. North America Infectious Disease Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Instruments
        3. Services and Software
      3. North America Infectious Disease Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Isothermal Nucleic Acid Amplification Technology (INAAT)
        3. Immunodiagnostics
        4. DNA Microarray
        5. Clinical Microbiology
        6. DNA Sequencing and Next-Generation Sequencing (NGS)
      4. U.S.
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      5. Canada
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
    2. Europe
      1. Europe Infectious Disease Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
      2. Europe Infectious Disease Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Instruments
        3. Services and Software
      3. Europe Infectious Disease Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Isothermal Nucleic Acid Amplification Technology (INAAT)
        3. Immunodiagnostics
        4. DNA Microarray
        5. Clinical Microbiology
        6. DNA Sequencing and Next-Generation Sequencing (NGS)
      4. U.K.
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      5. Germany
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      6. France
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      7. Spain
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      8. Italy
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      9. Russia
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      10. Nordic
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      11. Benelux
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      12. Rest of Europe
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
    3. APAC
      1. APAC Infectious Disease Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
      2. APAC Infectious Disease Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Instruments
        3. Services and Software
      3. APAC Infectious Disease Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Isothermal Nucleic Acid Amplification Technology (INAAT)
        3. Immunodiagnostics
        4. DNA Microarray
        5. Clinical Microbiology
        6. DNA Sequencing and Next-Generation Sequencing (NGS)
      4. China
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      5. Korea
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      6. Japan
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      7. India
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      8. Australia
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      9. Taiwan
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      10. South East Asia
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      11. Rest of Asia-Pacific
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
    4. Middle East and Africa
      1. Middle East and Africa Infectious Disease Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
      2. Middle East and Africa Infectious Disease Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Instruments
        3. Services and Software
      3. Middle East and Africa Infectious Disease Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Isothermal Nucleic Acid Amplification Technology (INAAT)
        3. Immunodiagnostics
        4. DNA Microarray
        5. Clinical Microbiology
        6. DNA Sequencing and Next-Generation Sequencing (NGS)
      4. UAE
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      5. Turkey
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      6. Saudi Arabia
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      7. South Africa
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      8. Egypt
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      9. Nigeria
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      10. Rest of MEA
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
    5. LATAM
      1. LATAM Infectious Disease Diagnostics Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
      2. LATAM Infectious Disease Diagnostics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Assays, Kits, and Reagents
        2. Instruments
        3. Services and Software
      3. LATAM Infectious Disease Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR)
        2. Isothermal Nucleic Acid Amplification Technology (INAAT)
        3. Immunodiagnostics
        4. DNA Microarray
        5. Clinical Microbiology
        6. DNA Sequencing and Next-Generation Sequencing (NGS)
      4. Brazil
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      5. Mexico
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      6. Argentina
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      7. Chile
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      8. Colombia
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
      9. Rest of LATAM
        1. Hepatitis
        2. Human Immunodeficiency Virus (HIV)
        3. Chlamydia Trachomatis Genital Infection
        4. Gonorrhea (CT/NG)
        5. Hospital-Acquired Infections
        6. Human Papillomavirus (HPV)
        7. Tuberculosis (TB)
        8. Influenza
        9. Assays, Kits, and Reagents
        10. Instruments
        11. Services and Software
        12. Polymerase Chain Reaction (PCR)
        13. Isothermal Nucleic Acid Amplification Technology (INAAT)
        14. Immunodiagnostics
        15. DNA Microarray
        16. Clinical Microbiology
        17. DNA Sequencing and Next-Generation Sequencing (NGS)
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.